Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
3.620
+0.150 (4.32%)
At close: Apr 28, 2026, 4:00 PM EDT
3.684
+0.064 (1.78%)
After-hours: Apr 28, 2026, 7:55 PM EDT
Evolent Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Evolent Health stock have an average target of 7.93, with a low estimate of 3.00 and a high estimate of 18. The average target predicts an increase of 119.06% from the current stock price of 3.62.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Evolent Health stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 15 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $6 | Buy | Maintains | $12 → $6 | +65.75% | Mar 2, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +10.50% | Feb 26, 2026 |
| UBS | UBS | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +38.12% | Feb 26, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $10 → $6 | Strong Buy | Maintains | $10 → $6 | +65.75% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Maintains $15 → $4 | Strong Buy | Maintains | $15 → $4 | +10.50% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
2.51B
from 1.88B
Increased by 33.89%
Revenue Next Year
2.91B
from 2.51B
Increased by 15.84%
EPS This Year
0.13
from -5.07
EPS Next Year
0.39
from 0.13
Increased by 198.71%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 2.7B | 3.4B | ||||
| Avg | 2.5B | 2.9B | ||||
| Low | 2.4B | 2.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 44.2% | 34.0% | ||||
| Avg | 33.9% | 15.8% | ||||
| Low | 26.0% | 3.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.37 | 0.65 | |||
| Avg | 0.13 | 0.39 | |||
| Low | -0.04 | 0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 396.5% | |||
| Avg | - | 198.7% | |||
| Low | - | 4.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.